52,630 Shares of Palvella Therapeutics, Inc. $PVLA Bought by Nan Fung Trinity HK Ltd.

Nan Fung Trinity HK Ltd. bought a new stake in Palvella Therapeutics, Inc. (NASDAQ:PVLA) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 52,630 shares of the company’s stock, valued at approximately $7,259,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PVLA. First Light Asset Management LLC increased its position in Palvella Therapeutics by 38.3% in the 1st quarter. First Light Asset Management LLC now owns 980,758 shares of the company’s stock worth $122,251,000 after buying an additional 271,617 shares during the period. BlackRock Inc. bought a new stake in shares of Palvella Therapeutics in the second quarter valued at approximately $140,343,000. Jennison Associates LLC boosted its position in shares of Palvella Therapeutics by 65.3% in the first quarter. Jennison Associates LLC now owns 640,611 shares of the company’s stock valued at $79,852,000 after acquiring an additional 253,128 shares during the period. Siren L.L.C. grew its stake in shares of Palvella Therapeutics by 243.3% in the first quarter. Siren L.L.C. now owns 257,485 shares of the company’s stock worth $32,096,000 after acquiring an additional 182,485 shares during the last quarter. Finally, Primecap Management Co. CA acquired a new stake in shares of Palvella Therapeutics in the second quarter worth $39,150,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

Palvella Therapeutics Stock Performance

Shares of NASDAQ:PVLA opened at $153.18 on Friday. Palvella Therapeutics, Inc. has a twelve month low of $72.22 and a twelve month high of $179.95. The business has a fifty day moving average of $143.62 and a 200-day moving average of $129.63.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($1.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.78) by $0.08. As a group, research analysts forecast that Palvella Therapeutics, Inc. will post -6.29 earnings per share for the current year.

Insider Activity at Palvella Therapeutics

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,313 shares of the firm’s stock in a transaction dated Wednesday, October 21st. The shares were sold at an average price of $124.58, for a total value of $537,313.54. Following the completion of the sale, the chief operating officer owned 2,165 shares in the company, valued at approximately $269,715.70. This trade represents a 66.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jeffrey S. Martini sold 6,250 shares of the business’s stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $166.98, for a total transaction of $1,043,625.00. Following the completion of the transaction, the insider directly owned 4,266 shares of the company’s stock, valued at approximately $712,336.68. This represents a 59.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 67,306 shares of company stock worth $9,800,571. 17.20% of the stock is owned by insiders.

Analyst Ratings Changes

PVLA has been the topic of a number of research reports. Oppenheimer boosted their target price on shares of Palvella Therapeutics from $210.00 to $232.00 and gave the stock an “outperform” rating in a research report on Friday, November 6th. HC Wainwright started coverage on shares of Palvella Therapeutics in a report on Friday, November 6th. They issued a “strong-buy” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Palvella Therapeutics in a report on Friday, September 25th. Truist Financial set a $207.00 price target on shares of Palvella Therapeutics in a research report on Wednesday, August 5th. Finally, Raymond James Financial set a $226.00 price target on shares of Palvella Therapeutics in a research report on Friday, October 16th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Palvella Therapeutics has a consensus rating of “Buy” and an average price target of $213.85.

About Palvella Therapeutics

Palvella Therapeutics is a clinical-stage biopharmaceutical company developing treatments for patients with rare and serious diseases, with a focus on conditions affecting the skin and related tissues. The company is based in Wayne, Pennsylvania. Its pipeline includes QTORIN-based topical drug candidates, which use the company’s platform to deliver medicines locally to affected tissue. Programs are being developed for conditions including microcystic lymphatic malformations and cutaneous venous malformations; these candidates are investigational and have not been established as approved treatments.